In silico Study of New Vascular Endothelial Growth Factor Receptor Inhibitors for The Treatment of Hepatocellular Carcinoma

Novel therapeutics are desperately needed for the difficult-to-treat and very lethal malignancy known as hepatocellular carcinoma (HCC). The first drug now authorized treatment of individuals with advanced HCC is sorafenib. To find novel Vascular Endothelial Growth Factor Receptor Inhibitors prospective candidate HCC, an in-silico technique was used in this case. Docking investigations were conducted using GOLD Suite (v. 5.7.1) from Cambridge Crystallographic Data Centre (CCDC). docking/scoring methods CCDC validated by reproducing docking interactions poses Sorafenib. Based on their PLP fitness, compounds I–X sorafenib graded ability to inhibit VEGF. Compounds II, III VIII among other ligands exhibit higher binding energies than standard that give fitness value (80.4).